Gyre Therapeutics CEO reports sale of 10,315 shares

GYRE Therapeutics, Inc. Chief Executive Officer Luo Ying reported indirect open-market sales of company common stock held by a spouse.

Rhea-AI Filing Summary

GYRE Therapeutics, Inc. Chief Executive Officer Luo Ying reported indirect open-market sales of company common stock held by a spouse. On May 5–6, 2026, a total of 10,315 shares of common stock were sold in two transactions at weighted average prices of $8.01 and $8.04 per share. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025, indicating they were pre-arranged. Following these transactions, indirect holdings reported as owned through the spouse totaled 2,565,226 shares of common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,315 shares

Net Sell 2 txns

Insider Luo Ying

Role Chief Executive Officer

Sold 10,315 shs ($83K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,136	$8.04	$81K
Sale	Common Stock	179	$8.01	$1K

Holdings After Transaction: Common Stock — 2,565,226 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold total: 10,315 shares Shares sold May 6, 2026: 10,136 shares at $8.04/share Shares sold May 5, 2026: 179 shares at $8.01/share +3 more

6 metrics

Shares sold total 10,315 shares Open-market sales on May 5–6, 2026

Shares sold May 6, 2026 10,136 shares at $8.04/share Open-market sale, indirect by spouse

Shares sold May 5, 2026 179 shares at $8.01/share Open-market sale, indirect by spouse

Price range for May 6 sales $8.00–$8.071/share Weighted average price disclosure footnote

Indirect holdings after sales 2,565,226 shares Common stock held indirectly by spouse after May 6, 2026

Trading plan adoption date March 13, 2025 Rule 10b5-1 trading plan for these sales

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, indirect ownership

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

indirect ownership financial

"direct_or_indirect: I, ownership_type: indirect, nature_of_ownership: By Spouse"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gyre Therapeutics (GYRE) disclose in this Form 4?

Gyre Therapeutics disclosed that CEO Luo Ying’s spouse sold 10,315 shares of common stock in open-market transactions. The sales occurred on May 5–6, 2026, at weighted average prices of $8.01 and $8.04 per share, and are reported as indirect ownership changes.

How many Gyre Therapeutics (GYRE) shares were sold and at what prices?

A total of 10,315 Gyre Therapeutics common shares were sold across two days. On May 5, 179 shares were sold at a weighted average price of $8.01, and on May 6, 10,136 shares were sold at a weighted average price of $8.04 per share.

Were the Gyre Therapeutics (GYRE) insider sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on March 13, 2025. Such plans pre-schedule trades, indicating these sales were arranged in advance rather than timed in response to short-term market developments.

Does Gyre Therapeutics (GYRE) CEO Luo Ying still hold shares after these sales?

Yes. After the reported sales, indirect holdings through the CEO’s spouse totaled 2,565,226 common shares. This indicates the 10,315 shares sold represent a relatively small portion of the overall position reported as indirectly owned in the Form 4.

How are the insider holdings characterized in the Gyre Therapeutics (GYRE) Form 4?

The Form 4 characterizes the reported holdings as indirect, with the nature of ownership listed as “By Spouse.” This means the shares are legally held by the spouse, but the CEO is still considered a reporting person for these securities under SEC beneficial ownership rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 09:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luo Ying

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		S(1)		179	D	$8.01	2,575,362	I	By Spouse
Common Stock	05/06/2026		S(1)		10,136	D	$8.04(2)	2,565,226	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Thomas Eastling, as attorney-in-fact for Ying Luo	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)